LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. TI=Nalbuphine and pruritus
  2. AU="Enrique Parras-Garrido"

Suchergebnis

Treffer 1 - 10 von insgesamt 62

Suchoptionen

  1. Artikel ; Online: Effect of adding nalbuphine to intrathecal bupivacaine with morphine on postoperative nausea and vomiting and pruritus after elective cesarean delivery: a randomized double blinded study.

    Ibrahim, Abdelrady S / Aly, Mohamed G / Thabet, Mostafa E / Abdelaziz, Mohamed R

    Minerva anestesiologica

    2018  Band 85, Heft 3, Seite(n) 255–262

    Abstract: ... on postoperative nausea and vomiting and pruritus after a cesarean delivery.: Methods: Eighty parturient undergoing elective ... pruritus. Onset and duration of sensory blockade, Visual Analog Scale for pain, the first time to ask ... and pruritus severity scores and number of patients developed nausea and vomiting and pruritus were ...

    Abstract Background: The use of intrathecal morphine may result in serious side effects in parturients undergoing cesarean delivery. Nalbuphine, is a mu receptor antagonist and a ĸappa receptor agonist. Combinations of opioid agonist and agonist antagonist can decrease the incidence of opioid related side effects. We aimed to investigate the effect of adding nalbuphine, to intrathecal morphine on postoperative nausea and vomiting and pruritus after a cesarean delivery.
    Methods: Eighty parturient undergoing elective cesarean delivery under spinal anesthesia were randomized into two similar groups. Group 1: received 10 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine. Group 2: received as a group 1 plus 0.5 mg nalbuphine, with total volume 2.5 mL in both groups. Measurements: Data on the severity of nausea and vomiting were collected using a numerical rating scale and visual analogue scale was used to quantify pruritus. Onset and duration of sensory blockade, Visual Analog Scale for pain, the first time to ask for rescue analgesia and total rescue analgesic consumption were recorded.
    Results: Nausea and vomiting and pruritus severity scores and number of patients developed nausea and vomiting and pruritus were significantly lower (P<0.001) in group 2. Onset and duration of sensory block, time to first request for rescue analgesia, Visual Analog Scale for pain and paracetamol consumption showed no statistically differences between both groups (P>0.05).
    Conclusions: We concluded that the addition of nalbuphine to intrathecal bupivacaine plus morphine significantly reduced the incidence and severity of postoperative nausea and vomiting and pruritus without affecting analgesic potency.
    Mesh-Begriff(e) Adult ; Analgesics, Opioid/administration & dosage ; Anesthesia, Obstetrical ; Anesthesia, Spinal ; Anesthetics, Local/administration & dosage ; Bupivacaine/administration & dosage ; Cesarean Section ; Double-Blind Method ; Drug Combinations ; Elective Surgical Procedures ; Female ; Humans ; Morphine/administration & dosage ; Nalbuphine/administration & dosage ; Postoperative Complications/prevention & control ; Postoperative Nausea and Vomiting/prevention & control ; Pregnancy ; Prospective Studies ; Pruritus/prevention & control ; Young Adult
    Chemische Substanzen Analgesics, Opioid ; Anesthetics, Local ; Drug Combinations ; Morphine (76I7G6D29C) ; Nalbuphine (L2T84IQI2K) ; Bupivacaine (Y8335394RO)
    Sprache Englisch
    Erscheinungsdatum 2018-05-30
    Erscheinungsland Italy
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 123584-9
    ISSN 1827-1596 ; 0026-4717 ; 0375-9393
    ISSN (online) 1827-1596
    ISSN 0026-4717 ; 0375-9393
    DOI 10.23736/S0375-9393.18.12751-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Comparison of postoperative analgesia and side effects in pediatric laparoscopic surgery with morphine and nalbuphine.

    Chen, Jia / Wang, Cheng-Yu / Zhong, John Wei / Cai, Yu-Hang / Zhang, Jianmin / Wang, Fang / Zhang, Mazhong / Gu, Hongbin / Ma, Hong-Yu / Wang, Zhen / Wu, Junzheng / Liu, Hua-Cheng

    iScience

    2024  Band 27, Heft 3, Seite(n) 109287

    Abstract: ... depression (RR ≤ 10/min) (4.8% vs. 38.6%, p < 0.001), PONV (2.4% vs. 18.1%, p = 0.002), and pruritus (0% vs ... between nalbuphine and morphine in children undergoing laparoscopic surgery. One hundred ninety children ... pruritus compared with morphine in pediatric laparoscopic surgery. ...

    Abstract There is currently no consensus on the optimal perioperative pain management strategy involving specific opioids. This study aims to compare the postoperative analgesia, the associated side effects between nalbuphine and morphine in children undergoing laparoscopic surgery. One hundred ninety children were randomly assigned to nalbuphine (0.2 mg/kg) or morphine (0.2 mg/kg). Nalbuphine's analgesic effect was non-inferior to morphine, with similar total rescue analgesic consumption during PACU stay (0.03 ± 0.05mg vs. 0.04 ± 0.06 mg, p > 0.05). Nalbuphine group had a lower incidence of respiratory depression (RR ≤ 10/min) (4.8% vs. 38.6%, p < 0.001), PONV (2.4% vs. 18.1%, p = 0.002), and pruritus (0% vs. 16.9%, p < 0.001) than morphine. Additionally, nalbuphine showed a shorter laryngeal mask airway removal time (13.9 [12.7, 15.1]) compared with morphine (17.0 [15.1, 18.9], p = 0.011). Nalbuphine provides equipotent analgesia with significantly lower incidences of respiratory depression, PONV, and pruritus compared with morphine in pediatric laparoscopic surgery.
    Sprache Englisch
    Erscheinungsdatum 2024-02-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2024.109287
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Efficacy and safety of nalbuphine for epidural labor analgesia at high altitude: An observational study.

    Wang, Pengxia / Yu, Ping / Cheng, Sen / Wu, Xinting / Li, Xuemei / Zeng, Yinying / Liu, Shanshan

    Medicine

    2024  Band 103, Heft 12, Seite(n) e37509

    Abstract: ... at delivery, 24-hour postpartum bleeding, and pruritus (P < .05). However, between the 2 groups, there were no ... and neonatal outcomes from combining nalbuphine with sufentanil and ropivacaine in 600 women during ... The nalbuphine group received nalbuphine, sufentanil, and ropivacain, the control group only received sufentanil ...

    Abstract Xining is located at the eastern edge of the Qinghai-Tibet Plateau, with an average altitude of >7000 feet (>2000 m). Nalbuphine is a kappa-opioid receptor agonist that can provide analgesia with fewer side effects than other opioid analgesics. This study aimed to evaluate pain control, side effects, and neonatal outcomes from combining nalbuphine with sufentanil and ropivacaine in 600 women during epidural anesthesia while giving birth at a high altitude in Xining, China. A total of 600 parturients receiving epidural labor analgesia were randomly divided into 2 groups, each group 300 parturients. The nalbuphine group received nalbuphine, sufentanil, and ropivacain, the control group only received sufentanil and ropivacain. The analgesic effect was evaluated through the Visual Analogue Scale scores. Neonatal outcomes were mainly evaluated through the Apgar Scores. Compared to the control group, the nalbuphine group showed lower Visual Analogue Scale scores at all time points after analgesia (P < .05). In comparison with the control group, parturients in the nalbuphine group showed lower incidence rates of fever at delivery, 24-hour postpartum bleeding, and pruritus (P < .05). However, between the 2 groups, there were no statistically significant differences in the remaining maternal and infant outcomes and neonatal outcomes (P > .05). Moreover, no adverse effects on neonatal outcomes were observed. The findings from this study support findings from previous studies that nalbuphine provided safe epidural analgesia without significant side effects for the mother and infant, and showed both safety and efficacy when used during labor at high altitude.
    Mesh-Begriff(e) Female ; Humans ; Infant, Newborn ; Pregnancy ; Altitude ; Analgesia, Epidural/adverse effects ; Analgesia, Obstetrical/adverse effects ; Analgesics/adverse effects ; Analgesics, Opioid/adverse effects ; Anesthetics, Local ; Nalbuphine/adverse effects ; Pain/etiology ; Sufentanil/therapeutic use
    Chemische Substanzen Analgesics ; Analgesics, Opioid ; Anesthetics, Local ; Nalbuphine (L2T84IQI2K) ; Sufentanil (AFE2YW0IIZ)
    Sprache Englisch
    Erscheinungsdatum 2024-03-22
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Observational Study ; Randomized Controlled Trial
    ZDB-ID 80184-7
    ISSN 1536-5964 ; 0025-7974
    ISSN (online) 1536-5964
    ISSN 0025-7974
    DOI 10.1097/MD.0000000000037509
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Use of Nalbuphine for Treatment of Neuraxial Opioid-Induced Pruritus: A Systematic Review and Meta-Analysis.

    Tubog, Tito D / Harenberg, Jennifer L / Buszta, Kristina / Hestand, Jennifer D

    AANA journal

    2019  Band 87, Heft 3, Seite(n) 222–230

    Abstract: ... for established pruritus. The pharmacokinetics and pharmacodynamic profiles of nalbuphine make this drug ideal ... for the treatment of established pruritus. The primary outcome of this systematic review and meta-analysis was ... Opioid-induced pruritus is prevalent after neuraxial administration of opioid. A number ...

    Abstract Opioid-induced pruritus is prevalent after neuraxial administration of opioid. A number of preventive measures have been reported; however, only a few studies evaluated treatment strategies for established pruritus. The pharmacokinetics and pharmacodynamic profiles of nalbuphine make this drug ideal for the treatment of established pruritus. The primary outcome of this systematic review and meta-analysis was the incidence of pruritus after neuraxial opioid administration. Secondary outcomes were the incidence of sedation and postoperative nausea and vomiting. Pooled estimates were reported by calculating the risk ratio (RR) with 95% confidence interval (CI). Five trials consisting of 494 patients were included for analysis. There was a low quality of evidence that nalbuphine was effective in reducing the incidence of pruritus compared with active control (RR, 0.59; 95% CI, 0.38 to 0.93; P = .02). Conversely, there was no difference between the incidence of sedation (RR, 1.06; 95% CI, 0.42 to 2.71; P = .90) and postoperative nausea and vomiting (RR, 1.58, 95% CI, 0.75 to 3.31; P = .23). Although large studies are needed to decrease heterogeneity across studies, the current review showed that nalbuphine appears to reduce the incidence of opioid-induced pruritus.
    Mesh-Begriff(e) Analgesics, Opioid/administration & dosage ; Analgesics, Opioid/adverse effects ; Analgesics, Opioid/therapeutic use ; Humans ; Morphine/adverse effects ; Nalbuphine/administration & dosage ; Nalbuphine/therapeutic use ; Nurse Anesthetists ; Pain, Postoperative/prevention & control ; Postoperative Nausea and Vomiting/drug therapy ; Pruritus/drug therapy
    Chemische Substanzen Analgesics, Opioid ; Morphine (76I7G6D29C) ; Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 2019-10-23
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 603605-3
    ISSN 2162-5239 ; 0094-6354
    ISSN (online) 2162-5239
    ISSN 0094-6354
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.

    Eudy-Byrne, Rena / Riggs, Matthew / Hawi, Amale / Sciascia, Thomas / Rohatagi, Shashank

    British journal of clinical pharmacology

    2023  Band 89, Heft 7, Seite(n) 2088–2101

    Abstract: ... to describe the exposure-response (E-R) relationship between nalbuphine exposure and two widely used rating ... doses of nalbuphine extended release (ER) or placebo, were used for the analysis. A two-compartment PK ... Aims: Population pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) models were used ...

    Abstract Aims: Population pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) models were used to describe the exposure-response (E-R) relationship between nalbuphine exposure and two widely used rating scales for itch: the Numerical Rating Scale for the subject's 'average'; itch experience (NRS-AV) and the Worst Itch (WI-NRS), with 24-h recall. Simulations based on the model E-R relationship were used to support dose selection for Phase 3 clinical trials and were evaluated with a target of reducing the 7-day average of the 24-h WI-NRS by at least 30% from baseline in most of the analysis population.
    Methods: Data from two clinical trials (NCT02373215: 9 healthy subjects; NCT02174419: 62 subjects with PN), in patients with prurigo nodularis (PN) with moderate to severe itch who received treatment with either of two doses of nalbuphine extended release (ER) or placebo, were used for the analysis. A two-compartment PK model with serial zero and first-order oral absorption was used to describe drug exposure. A maximum effect (
    Results: The PK-PD model predicted the exposure-related reduction in both NRS-AV and WI-NRS over time with approximately 63% and 27% of
    Conclusion: Simulated dose response indicated that 108 and 162 mg BID doses result in the highest proportion of patients achieving at least a 30% reduction in NRS-AV and WI-NRS, respectively.
    Mesh-Begriff(e) Humans ; Prurigo/drug therapy ; Nalbuphine/adverse effects ; Pruritus/drug therapy
    Chemische Substanzen Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 2023-02-09
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15663
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Nalbuphine and pruritus.

    Elias, M

    Anaesthesia

    1997  Band 52, Heft 6, Seite(n) 613

    Mesh-Begriff(e) Analgesics, Opioid/adverse effects ; Antipruritics/therapeutic use ; Humans ; Nalbuphine/therapeutic use ; Pruritus/drug therapy
    Chemische Substanzen Analgesics, Opioid ; Antipruritics ; Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 1997-06
    Erscheinungsland England
    Dokumenttyp Letter
    ZDB-ID 80033-8
    ISSN 1365-2044 ; 0003-2409
    ISSN (online) 1365-2044
    ISSN 0003-2409
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Nalbuphine and pruritus.

    Ramsay, M A / Flanders, D

    Anaesthesia

    1997  Band 52, Heft 10, Seite(n) 1023

    Mesh-Begriff(e) Analgesics, Opioid/antagonists & inhibitors ; Antipruritics/pharmacology ; Humans ; Nalbuphine/pharmacology ; Pain, Postoperative/drug therapy ; Piperidines/antagonists & inhibitors ; Pruritus/drug therapy
    Chemische Substanzen Analgesics, Opioid ; Antipruritics ; Piperidines ; Nalbuphine (L2T84IQI2K) ; remifentanil (P10582JYYK)
    Sprache Englisch
    Erscheinungsdatum 1997-10
    Erscheinungsland England
    Dokumenttyp Letter ; Comment
    ZDB-ID 80033-8
    ISSN 1365-2044 ; 0003-2409
    ISSN (online) 1365-2044
    ISSN 0003-2409
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

    Inan, Saadet / Dun, Nae J / Cowan, Alan

    Molecules (Basel, Switzerland)

    2021  Band 26, Heft 18

    Abstract: ... with nalbuphine (0.3-10 mg/kg) and then a submaximal dose of pruritogens were administered and the number ... nalbuphine, are in clinical studies for antipruritic effects in chronic itch of systemic and skin diseases ... of nalbuphine against TAT-HIV-1 protein (controls HIV transcription)-, deoxycholic acid (DCA, bile acid)-, and ...

    Abstract Antipruritic effects of kappa opioid receptor (KOR) agonists have been shown in rodent models of acute and chronic scratching (itchlike behavior). Three KOR agonists, nalfurafine, difelikefalin, and nalbuphine, are in clinical studies for antipruritic effects in chronic itch of systemic and skin diseases. Nalfurafine (in Japan) and difelikefalin (in the USA) were approved to be used in the treatment of chronic itch in hemodialysis patients. The FDA-approved nalbuphine has been used in clinic for over 40 years, and it is the only narcotic agonist that is not scheduled. We aimed to study (a) antiscratch activity of nalbuphine against TAT-HIV-1 protein (controls HIV transcription)-, deoxycholic acid (DCA, bile acid)-, and chloroquine (CQ)-induced scratching in a mouse model of acute itch; and (b) whether the effect of nalbuphine is produced via KORs. First, dose-responses were developed for pruritogens. Mice were pretreated with nalbuphine (0.3-10 mg/kg) and then a submaximal dose of pruritogens were administered and the number of scratching bouts was counted. To study if the antiscratch effect of nalbuphine is produced via KOR, we used KOR knock out mice and pharmacologic inhibition of KORs using nor-binaltorphimine, a KOR antagonist. For this aim, we used CQ as a pruritogen. We found that: (a) TAT-HIV-1 protein elicits scratching in a dose-dependent manner; (b) nalbuphine inhibits scratching induced by TAT-HIV-1, DCA, and CQ dose-dependently; and (c) nalbuphine inhibits scratching induced by CQ through KORs. In conclusion, nalbuphine inhibits scratching elicited by multiple pruritogens.
    Mesh-Begriff(e) Animals ; Antipruritics/pharmacology ; Antipruritics/therapeutic use ; Behavior, Animal/drug effects ; Chloroquine/toxicity ; Deoxycholic Acid/toxicity ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Male ; Mice ; Nalbuphine/pharmacology ; Nalbuphine/therapeutic use ; Naltrexone/analogs & derivatives ; Naltrexone/pharmacology ; Naltrexone/therapeutic use ; Narcotic Antagonists/pharmacology ; Narcotic Antagonists/therapeutic use ; Pruritus/chemically induced ; Pruritus/prevention & control ; Receptors, Opioid, kappa/agonists ; Receptors, Opioid, kappa/antagonists & inhibitors ; Receptors, Opioid, kappa/genetics ; Receptors, Opioid, kappa/metabolism ; tat Gene Products, Human Immunodeficiency Virus/toxicity
    Chemische Substanzen Antipruritics ; Narcotic Antagonists ; Receptors, Opioid, kappa ; tat Gene Products, Human Immunodeficiency Virus ; Deoxycholic Acid (005990WHZZ) ; norbinaltorphimine (36OOQ86QM1) ; Naltrexone (5S6W795CQM) ; Chloroquine (886U3H6UFF) ; Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 2021-09-11
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules26185517
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Nalbuphine for spinal anesthesia: A systematic review and meta-analysis.

    Yu, Pan / Zhang, Jie / Wang, Jun

    Pain practice : the official journal of World Institute of Pain

    2021  Band 22, Heft 1, Seite(n) 91–106

    Abstract: ... RR = 0.19, 95% CI = 0.08-0.43, p < 0.01), and the occurrence of pruritus (RR = 0.23, 95% CI = 0.10-0 ... from that of the potent opioids, but the occurrence of hypotension, shivering, and pruritus was lower than the potent ... been clinically studied, but the safety and efficiency of nalbuphine as an adjuvant ...

    Abstract Purpose: Various adjuvants for prolongation of intra-operative and postoperative analgesia have been clinically studied, but the safety and efficiency of nalbuphine as an adjuvant to local anesthetics in spinal anesthesia remains unconfirmed. Therefore, we conducted a meta-analysis about the effect of nalbuphine as an adjuvant to local anesthetics in spinal anesthesia in regard to time of onset of sensory blockade and motor blockade, duration of motor blockade, 2-segment sensory regression time, the duration of analgesia, and incidence of side effects to provide a reliable basis for clinical application.
    Methods: Databases, including PubMed, Cochrane, EMBASE, Web of Science, CNKI, CBM, WanFang, and Viper, were searched for eligible studies. Data were extracted according to the proposed inclusion and exclusion criteria, RevMan version 5.3 and Stata 16 were selected to perform meta-analysis.
    Results: Eighteen published studies including 1633 patients met the inclusion criteria. The results showed that adding nalbuphine to local anesthetics for spinal anesthesia can prolong two-segment sensory regression time (mean difference [MD] = 24.31; 95% confidence interval [CI] = 19.61-29.00, p < 0.001) and the duration of analgesia (MD = 118.11; 95% CI = 71.34-164.89, p < 0.001) without significantly increasing the incidence of adverse reactions in comparison to normal saline group. In addition, the analgesic effect of nalbuphine group was not statistically different from that of control group when compared with the potent opioid group, but the occurrence of hypotension (risk ratio [RR] = 0.35, 95% CI = 0.18-0.68, p < 0.01), the occurrence of shivering (RR = 0.19, 95% CI = 0.08-0.43, p < 0.01), and the occurrence of pruritus (RR = 0.23, 95% CI = 0.10-0.53, p < 0.01) was lower than the potent opioid group.
    Conclusions: Nalbuphine as additives to local anesthetics can significantly prolong the two segments of sensory block and the average duration of analgesia without increasing the incidence of adverse reactions when compared with normal saline group. In addition, the analgesic efficacy of nalbuphine served as an adjunct to local anesthetics was clinically not different from that of the potent opioids, but the occurrence of hypotension, shivering, and pruritus was lower than the potent opioids.
    Mesh-Begriff(e) Analgesics, Opioid/adverse effects ; Anesthesia, Spinal/adverse effects ; Anesthetics, Local ; Humans ; Nalbuphine
    Chemische Substanzen Analgesics, Opioid ; Anesthetics, Local ; Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 2021-06-02
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ZDB-ID 2151272-3
    ISSN 1533-2500 ; 1530-7085
    ISSN (online) 1533-2500
    ISSN 1530-7085
    DOI 10.1111/papr.13021
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Prophylactic Nalbuphine to Prevent Neuraxial Opioid-Induced Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    Tubog, Tito D / Harenberg, Jennifer L / Buszta, Kristina / Hestand, Jennifer D

    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses

    2018  Band 34, Heft 3, Seite(n) 491–501.e8

    Abstract: ... pruritus therapy and severity of pruritus episodes. However, nalbuphine did not cause sedation and affect ... pain scores.: Conclusions: Prophylactic nalbuphine decreased the incidence and severity of pruritus ... that nalbuphine was effective in reducing the incidence of pruritus in all patient population (RR, 0.66; 95% CI, 0 ...

    Abstract Purpose: Evaluate the efficacy of prophylactic nalbuphine in preventing neuraxial opioid-induced pruritus.
    Design: Systematic review and meta-analysis.
    Methods: Following the PRISMA statement, PubMed, CINAHL, Cochrane and EMBASE were searched for eligible studies.
    Findings: A total of 17 trials consisting of 1,052 patients were evaluated. Compared to placebo, there is low quality of evidence that nalbuphine was effective in reducing the incidence of pruritus in all patient population (RR, 0.66; 95% CI, 0.52 to 0.83; P = .0004) and obstetrics (RR, 0.81; 95% CI, 0.67 to 0.98; P = .03). We also found moderate quality of evidence that nalbuphine lowered pruritus in non-obstetrics, the number of rescue pruritus therapy and severity of pruritus episodes. However, nalbuphine did not cause sedation and affect pain scores.
    Conclusions: Prophylactic nalbuphine decreased the incidence and severity of pruritus without adverse effects on sedation and analgesic effect of opioids.
    Mesh-Begriff(e) Analgesics, Opioid/administration & dosage ; Analgesics, Opioid/adverse effects ; Female ; Humans ; Incidence ; Nalbuphine/administration & dosage ; Nalbuphine/adverse effects ; Pain/drug therapy ; Pregnancy ; Pruritus/chemically induced ; Pruritus/epidemiology ; Pruritus/prevention & control ; Randomized Controlled Trials as Topic
    Chemische Substanzen Analgesics, Opioid ; Nalbuphine (L2T84IQI2K)
    Sprache Englisch
    Erscheinungsdatum 2018-10-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 1329844-6
    ISSN 1532-8473 ; 0883-9433 ; 1089-9472
    ISSN (online) 1532-8473
    ISSN 0883-9433 ; 1089-9472
    DOI 10.1016/j.jopan.2018.06.098
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang